tradingkey.logo
tradingkey.logo

Cytek Biosciences Inc

CTKB
5.100USD
+0.030+0.59%
終値 12/26, 16:00ET15分遅れの株価
652.11M時価総額
損失額直近12ヶ月PER

Cytek Biosciences Inc

5.100
+0.030+0.59%

詳細情報 Cytek Biosciences Inc 企業名

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Cytek Biosciences Incの企業情報

企業コードCTKB
会社名Cytek Biosciences Inc
上場日Jul 23, 2021
最高経営責任者「CEO」Jiang (Wenbin)
従業員数648
証券種類Ordinary Share
決算期末Jul 23
本社所在地47215 Lakeview Boulevard
都市FREMONT
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号94538
電話番号18779229835
ウェブサイトhttps://cytekbio.com
企業コードCTKB
上場日Jul 23, 2021
最高経営責任者「CEO」Jiang (Wenbin)

Cytek Biosciences Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
12.36K
+21.43%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
地域別USD
会社名
収益
比率
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
事業別
地域別
事業別USD
会社名
収益
比率
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
他の
67.30%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
他の
67.30%
種類
株主統計
比率
Investment Advisor
28.05%
Investment Advisor/Hedge Fund
22.30%
Hedge Fund
9.95%
Individual Investor
9.31%
Research Firm
1.43%
Pension Fund
1.21%
Bank and Trust
0.17%
Family Office
0.12%
Venture Capital
0.06%
他の
27.39%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
319
80.93M
70.83%
-2.20K
2025Q3
325
80.93M
70.98%
+589.69K
2025Q2
322
80.49M
71.67%
+1.88M
2025Q1
319
78.68M
72.45%
-13.77M
2024Q4
315
78.50M
69.87%
+2.46M
2024Q3
291
75.89M
70.06%
-1.14M
2024Q2
277
76.97M
68.86%
-4.44M
2024Q1
273
87.08M
76.11%
-12.82M
2023Q4
268
85.37M
77.21%
+1.48M
2023Q3
258
83.84M
73.24%
+597.32K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Millennium Management LLC
924.77K
0.73%
+429.33K
+86.66%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco S&P SmallCap Health Care ETF
0.26%
Royce Quant Small-Cap Quality Value ETF
0.22%
iShares S&P Small-Cap 600 Value ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
State Street SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.05%
WisdomTree US SmallCap Fund
0.04%
詳細を見る
Invesco S&P SmallCap Health Care ETF
比率0.26%
Royce Quant Small-Cap Quality Value ETF
比率0.22%
iShares S&P Small-Cap 600 Value ETF
比率0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.07%
State Street SPDR S&P 600 Small Cap Value ETF
比率0.06%
Avantis US Small Cap Equity ETF
比率0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
比率0.05%
Fidelity Enhanced Small Cap ETF
比率0.05%
Principal U.S. Small-Cap ETF
比率0.05%
WisdomTree US SmallCap Fund
比率0.04%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Cytek Biosciences Incの上位5名の株主は誰ですか?

Cytek Biosciences Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は15.38M株を保有しており、これは全体の12.09%に相当します。
Topline Capital Management, LLCは5.23M株を保有しており、これは全体の4.11%に相当します。
The Vanguard Group, Inc.は7.74M株を保有しており、これは全体の6.08%に相当します。
HHLR Advisors, Ltd.は6.66M株を保有しており、これは全体の5.23%に相当します。
Yan (Ming)は6.06M株を保有しており、これは全体の4.76%に相当します。

Cytek Biosciences Incの株主タイプ上位3種は何ですか?

Cytek Biosciences Incの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.

Cytek Biosciences Inc(CTKB)の株式を保有している機関の数はいくつですか?

2025Q4時点で、Cytek Biosciences Incの株式を保有している機関は319社あり、保有株式の総市場価値は約80.93Mで、全体の70.83%を占めています。2025Q3と比較して、機関の持ち株は-0.14%増加しています。

Cytek Biosciences Incの最大の収益源は何ですか?

FY2025Q2において、Biotechnology, pharmaceutical, distributor and CRO部門がCytek Biosciences Incにとって最大の収益を生み出しており、その金額は23.85Mで、全収益の52.30%を占めています。
KeyAI